Iovance Biotherapeutics (NASDAQ:IOVA) PT Raised to $25.00

Iovance Biotherapeutics is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for cancer and other diseases. The company's lead product candidate is FDA-approved POLATuzumab, an antibody-drug conjugate (ADC) targeting CD37, which is used to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

On July 12, 2022, Iovance Biotherapeutics announced that its common stock had been approved for trading on The NASDAQ Global Select Market under the symbol "IOVA" with a starting price of $25.00 per share. This was a significant milestone for the company as it marked the successful completion of its initial public offering (IPO) and provided additional capital to support the continued development and commercialization of POLATuzumab and other potential products in its pipeline.

Prior to the IPO, Iovance Biotherapeutics had been operating as a private company since its founding in 2013. The company's founders and key executives had previously worked at other biopharmaceutical companies, including Genzyme, Amgen, and Millennium Pharmaceuticals.

In addition to POLATuzumab, Iovance Biotherapeutics has several other product candidates in its pipeline, including IOV-301, an ADC targeting CD20, which is currently being evaluated in a Phase 1/2 clinical trial for relapsed/refractory DLBCL, and IOV-401, an ADC targeting CD37, which is being developed for the treatment of multiple myeloma. The company also has collaborations with other biopharmaceutical companies, including Genzyme, Amgen, and Millennium Pharmaceuticals.